FDA approves Genzyme’s Mozobil
Executive Summary
FDA approves Genzyme's Mozobil (plerixafor injection) for bone marrow transplant preparation Dec. 15, but the firm may face commercialization road bumps, analysts say. The product is indicated for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells from bone marrow in lymphoma and multiple myeloma patients undergoing transplants. Finding patients who effectively mobilize, however, is a challenge that may present a barrier for widespread use, Baird analyst Christopher Raymond says
|
FDA approves Genzyme's Mozobil (plerixafor injection) for bone marrow transplant preparation Dec. 15, but the firm may face commercialization road bumps, analysts say. The product is indicated for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells from bone marrow in lymphoma and multiple myeloma patients undergoing transplants. Finding patients who effectively mobilize, however, is a challenge that may present a barrier for widespread use, Baird analyst Christopher Raymond says. |